Table 2.
A list of recent clinical trials for SCI.
| Study Title | Intervention | Duration | Phase | Status | Sponsor |
|---|---|---|---|---|---|
| Intrathecal Transplantation of Autologous Bone Marrow-derived Mononuclear Cells for Treating Traumatic Acute Spinal Cord Injury | Lumbar injection Transplantation of autologous bone-marrow-derived mononuclear cells | 2020–2023 | II | recruiting | Shanghai Changzheng Hospital |
| Assessment of Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Spinal Cord Injury (SCI) Patients | Autologous bone-marrow-derived MSCs and Wharton-jelly-derived mesenchymal stem cells | 2017–2020 | I | completed | University of Jordan |
| Subarachnoid Administrations of Adults Autologous Mesenchymal Stromal Cells in SCI | Adult autologous mesenchymal bone marrow cells | 2019 | I | completed | Puerta de Hierro University Hospital |
| Intrathecal Administration (Pattern 100/3) of Expanded Autologous Adult Bone Marrow Mesenchymal Stem Cells in Established Chronic Spinal Cord Injuries | Autologous mesenchymal bone marrow cell injection | 2015–2017 | II | completed | Puerta de Hierro University Hospital |
| Autologous Bone Marrow Cell Transplantation in Persons with Acute Spinal Cord Injury—An Indian Pilot Study | Autologous mesenchymal bone marrow cells | 2011–2017 | I/II | completed | Indian Spinal Injuries Centre |
| Comparative Evaluation of Safety and Effectiveness of Autologous Bone Marrow Derived Mesenchymal Stem Cells (BM-MSC) vs. Adipose Tissue Derived Mesenchymal Stem Cells (AT-MSC) in the Treatment of Spinal Cord Injury (SCI) Patient | Intrathecal injection of autologous mesenchymal stem cells | 2016–2018 | I/II | completed | University of Jordan |
| CELLTOP Part II: A Phase II Clinical Trial of Autologous Adipose Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury | Intrathecal transplantation of autologous adipose-derived mesenchymal stem cells | 2020–2024 | II | recruiting | Mayo Clinic |
| Phase I Clinical Trial of Autologous Adipose Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury | Intrathecal delivery of autologous, adipose-derived mesenchymal stem cells | 2017–2019 | I | completed | Mohamad Bydon |
| Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for SCI | Cultured allogeneic adult umbilical-cord-derived mesenchymal stem cells | 2022–2026 | I | recruiting | Foundation for Orthopaedics and Regenerative Medicine |
| A Randomized Controlled Phase II, Two-Arm Study of Umbilical Cord Blood Cell Transplant (MC001) Into Injured Spinal Cord Followed by the Locomotor Training for Patients with Chronic Complete Spinal Cord Injuries (SCI) | Umbilical cord blood mononuclear stem cell (UCBMSC) transplant | 2022–2023 | II | recruiting | StemCyte, Inc. |
| Allogeneic Cord Blood for Neurological Diseases in Adults | Allogeneic umbilical cord blood therapy | 2022 | I | Not yet recruiting | The Medical Pavilion, Bahamas |
| Repeated Subarachnoid Administrations of Human Umbilical Cord Mesenchymal Stem Cells in Treating Spinal Cord Injury | Intrathecal administration of human umbilical cord mesenchymal stem cells | 2018–2020 | I/II | completed | Limin Rong, Third Affiliated Hospital, Sun Yat-Sen University |
| Allogeneic Mononuclear Umbilical Cord Blood Systemic Infusions for Adult Patients with Severe Acute Contusion Spinal Cord Injury: Phase I Safety Study and Phase IIa Primary Efficiency Study | I.V. infusions of human allogeneic umbilical cord blood mononuclear cells | 2013–2018 | I/IIa | completed | Sklifosovsky Institute of Emergency Care |
| A Single Center, Open Label, Single Group, Phase 1/2a Clinical Study to Evaluate the Safety and Exploratory Efficacy of Transplantation Therapy Using PSA-NCAM(+) NPC Derived From hESC Line in AIS-A Level of Sub-acute SCI(From 7 to 60 Days) | Neural precursor cells derived from human embryonic stem cell line | 2021–2023 | I/IIa | recruiting | S.Biomedics Co., Ltd. |
| A Multi-center, Double-blind, Randomized, Placebo-controlled, Delayed Start Phase II/III Study to Assess the Efficacy and Safety of Neuro-Cells in (Sub)Acute Spinal Cord Injury Patients | Intrathecal intervention with neuro-cells | 2022 | II/III | recruiting | Neuroplast |
| A 3 Months Open Phase I Study to Assess the Safety of the Intrathecal Application of Neuro-Cells in End Stage (Chronic) Traumatic Spinal Cord Injury Patients | Intrathecal application of neuro-cells | 2020–2021 | I | active, not recruiting | Neuroplast |
| The Safety of Autologous Human Schwann Cells (ahSC) in Subjects with Chronic Spinal Cord Injury (SCI) Receiving Rehabilitation | Autologous human Schwann cell transplantation | 2015–2019 | I | completed | W. Dalton Dietrich, University of Miami, Miami Project |
| Dose Escalation Study of AST-OPC1 in Spinal Cord Injury | AST-OPC1 injection | 2015–2018 | I/IIa | completed | Lineage Cell Therapeutics, Inc. |
Currently, only cell-therapy-based trials are available, and no gene-therapy-based trials were found; data were retrieved from ClinicalTrials.gov on 30 November 2022.